In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading this week, for the September 19th expiration. One of the key data points that goes into the price an option buyer is willing ...

Check Out Our Latest Stock Report on BNTX BioNTech Trading Down 3.3 % NASDAQ:BNTX opened at $118.14 on Friday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) climbed 5.4% mid-day Tuesday as remarks by RFK Jr, who clarified his stance as not being anti-vaccine or anti-industry, appeared to bolster investor ...

European equities traded in the US as American depositary receipts were trending lower late Tuesday morning, declining 0.73% to 1,352.77 on the S&P Europe Select ADR Index. From continental Europe, ...